Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Gold Price Ends Lower for Fourth Week Despite Rebound as Fed Rate Hike Bets Strengthen 
S&P Affirms Brazil’s BB Credit Rating with Stable Outlook Amid Fiscal Challenges 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Trump Threatens 100% Tariffs on Countries Imposing Digital Services Taxes on U.S. Tech Firms 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
US Dollar Slips After PCE Inflation Data Eases Fed Rate Hike Expectations 
Bank Regulation Rollbacks in the U.S. and UK Could Increase Financial Risks, Study Warns 
Australian Household Spending Rebounds Strongly in May as Travel and Dining Drive Consumer Growth 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
BOJ Hawk Signals Faster Interest Rate Hikes Amid Inflation Risks 
MBK Partners and Unison Capital have formed a consortium to acquire Osstem Implant. They are planning to buy the management rights of the South Korean dental equipment and supplies manufacturing company.
As per The Korea Times, the stock price of Osstem implant soared after the MBK Partners and Unison Capital Korea consortium announced their intention to acquire the dental supplies firm’s management rights via a tender offer.
It was explained that a tender offer is a type of bid that is commonly made to buy a publicly traded company from shareholders. The offer asks them to sell their stock holdings at a set price and usually at a premium.
Stock market investors reportedly responded in a good way to the bid as they flocked to buy the shares. Moreover, when the news came out, Osstem Implant’s stock price once reached KRW188,000, which is said to be its highest since it went public on the KOSPI market in 2007. The stock price closed at KRW186,300, or about $151, after an increase of 14.65% from the previous session.
As for the MBK Partner and Unison Capital’s consortium, they have tendered a price offer of KRW190,000 per share. Shareholders of the company may register at NH Investment to sell off their stake through the tender offer until Feb. 24.
"As Osstem Implant is an export company and top-tier implant material provider, MBK's strong global network is expected to stably support the firm's long-term growth and continuous R&D activities, while UCK's unparalleled dental industry insights will also provide the firm with solid future growth," an insider from the local capital market told The Korea Times this week.
Meanwhile, The Korea Herald reported that if the tender offer goes ahead as planned, the consortium will become Osstem Implat’s largest shareholder. The company’s chairman Choi Kyu Ok follows in second spot with 9.6% stake ownership, while the Korea Corporate Governance Improvement is third with its 6.57% share.
